Kornimate/medical-research-clean huggingface dataset:
study on antibody persistence and immune memory of inactivated covid-19 vaccine

Conditions: COVID-19

Summary: the study describe 1 year durability of humoral and cellular immune responses in 150 individuals who received covid-19 inactivated vaccine. all participants were recruited aged between 18 and 59 years old. every participant was familiarized with the aim of the study and asked to sign an informed consent agreement, and be required blood sampling at the day 0 of first dose vaccine and 1 month, 3 months, 6 months and 12 months after fully vaccination separately. from every sample, 10 ml, 10 ml, and 5 ml were dispensed in three vacuum blood collection tubes. peripheral blood lymphocytes cell (pbmc) were isolated with the two 10 ml samples contained heparin to detect immune memory cells and cytokines. rbd-igg and neutralizing antibody be detected by 5ml sample from separating gel vacuum tubes. every individual conducted a detailed analysis comparing neutralizing antibody, tem, tcm , and report on the cellular and humoral immunity 1 year after accept covid-19 vaccine.


Eligibility criteria:
inclusion criteria: * working at the cdc * between the ages of 18 and 59 * healthy * not vaccinated with covid-19 vaccine * agreed to take a blood sample exclusion criteria: * who cannot take the covid-19 vaccine due to some personal reasons * history of sars-cov, sars-cov-2, or middle east respiratory syndrome infection * high-risk epidemiology history within 14 days before enrolment (eg, travel or residence history in communities with case reports, or contact history with someone infected with sars-cov-2) * axillary temperature of more than 37·0℃ * history of allergy to any vaccine component.

Keywords: inactivated vaccine cohort study antibody persistence cellular immunity
healthy at home pilot

Conditions: COPD; COPD Exacerbation; Emphysema or COPD

Summary: the objective is to conduct a pilot-feasibility trial of the "healthy at home" program, a multimodal intervention aimed at preventing acute care needs among copd patients. the program will feature a digital platform and virtual pulmonary rehabilitation to facilitate complex care management of umass memorial health patients

the healthy at home project is a pilot program aimed at improving care for patients who have copd. this pilot aims to establish how self-management using a digital application, mobile health services, and support from a wellness coach can help achieve this goal. participation in this study involves participants downloading a smartphone app, answering questionnaires, and wearing a fitbit everyday, including during sleep throughout the 6-month study period. the investigators will ask that participants share their medical records and healthcare visit information through the secure study app, to help better understand how to treat patients with chronic health conditions. participants will additionally have the option to enroll in wellinks, a program that helps patients manage their breathing and copd symptoms and provides patients with at-home medical equipment, one-on-one personalized virtual support from specially trained clinicians and coaches, and a separate easy-to-use app for tracking and communication.

Eligibility criteria:
inclusion criteria: * receives healthcare through umass memorial health * is at least 18 years old * has a self-reported or emr observed diagnosis of copd * has access to a smartphone (iphone or android) to download and use the study app(s) * lives within the geographic area served by the mobile integrated health program exclusion criteria: * lacks capacity to consent * does not understand english * does not have internet access on their smartphone at home * are currently enrolled in another investigational clinical trial * are or have previously been enrolled in any wellinks program
strain - work-related stress among health professionals in switzerland

Conditions: Stress; Health Care Professionals; Work-Related Condition

Summary: the aim of this study is to identify work stressors, stress reactions and long-term consequences among nurses, physicians, medical-technical and medical-therapeutic professions in switzerland and to reduce those factors by an educational intervention for the supervisors.

methods: this study is a cross-sectional design and randomly selected hospitals, nursing homes and home care organizations. the study sample included nursing staff and midwives, physicians, medical-technical and medical-therapeutic professionals at all hierarchical levels. data were collected using self-report questionnaires and analysed using multiple regression models.

Eligibility criteria:
inclusion criteria: * employee within a participating health organization in switzerland * health care professional (nurse, medical-technical medical-therapeutical profession, physician) exclusion criteria: * health professionals without an fixed employment contract
intragastric balloon, air versus fluid filled: randomized prospective study

Conditions: Morbid Obesity; Weight Loss; Tolerance

Summary: gastric balloons are an evolving way of reducing weight. there are two types on the market, up to date. air filled balloons seem to be more safe, and more tolerable.

morbidly obese patients are categorized into two groups: the 1st group to whom intragastric air filled balloon and the 2nd group to whom saline filled balloon is applied for treatment of their morbid obesity. the aim of study is to compare both types of balloons regarding safety, efficacy and tolerance.

Eligibility criteria:
inclusion criteria: * morbidly obese patients exclusion criteria: * patient refused * non compliant patients * psychological patients * oesophageal varices, big hiatus hernia, ulcers * gastric vascular malformations

Keywords: morbid obesity gastric balloon weight loss tolerance safety
glucose meter study

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to evaluate if the meal marker and reminder feature of the contour meter along with education maintains or increases frequency of testing blood sugar after meals and enables behavioral changes that may lead to improvement in glycemic control.


Eligibility criteria:
inclusion criteria: 1. persons with type 1 or type 2 diabetes 2. persons who are on a pump or are taking at least 1 mealtime injection of insulin a day 3. persons at least 21 years of age 4. persons willing to complete all study visits and study procedures including: * using the meal-marker + reminder feature regularly (group 2 subjects only) * using the paper logbook provided (both groups) 5. testing their bg at least 3 times a day during the entire study. 6. persons who are able to speak, read and understand english 7. persons who are currently performing self-testing of blood glucose at home routinely (at least 3 times per day) for 4 weeks or more exclusion criteria: 1. persons who have been using a contour, breeze or breeze 2 meter regularly during the previous 6 months 2. persons who test over 6 times/day regularly 3. persons who wear a bg sensor 2 weeks or more during each month. 4. persons with home heath aides who assist with their bg testing. 5. persons with the following impairments which, in the opinion of the investigator, would seriously compromise the integrity of the study: * significant visual impairment * significant hearing impairment * cognitive disorder * significant unstable co-morbidity (with notable change within the past 3 months) 6. any other condition as per investigator's discretion
southend imaging study

Conditions: Cognition Disorders

Summary: the study objective is to correlate global cognition and episodic memory performance to resting state fmri functional connectivity. this is a non-treatment, prospective, natural history data collection study in a cross-sectional cohort of patients with cognitive impairment.

at present, magnetic resonance imaging (mri) is widely used along with other tests to help diagnose dementia, however diagnosis still remains challenging. there is currently a focus on the usefulness of resting state functionalmri (rs fmri) as a way of establishing differences in functional connectivity between healthy subjects and those with various neurodegenerative disorders. although the potential for rs fmri to be used as a biomarker for neurological diseases looks promising, further research is needed, especially regarding validation of normal values and seed-based functional connectivity. further research into this area will help to improve the ability to appropriately classify new subjects and ultimately allow use of rs functional connectivity as a biomarker. this is a nontreatment, prospective, natural history data collection that aims to analyse functional connectivity in a cohort of patients with suspected cognitive impairment. correlation of global cognition and episodic memory performance to resting state fmri functional connectivity will be evaluated. patient population will include patients over the age of 18 with cognitive impairment and age and gender matched controls. eligible patients will have to complete neuropsychological and clinical assessments and complete an fmri scan prior to enrolment.study duration is estimated at 4 years.

Eligibility criteria:
inclusion criteria: * informed consent * cognitive impairment * age from 18 to 100 years * on stable medication for 1 month before the screening visit; on or off cholinesterase inhibitors * fluency in english and adequate premorbid intellectual functioning exclusion criteria: * any contraindication to mri scanning * clinically significant psychiatric disorder (e.g. depression) * current clinically significant illness that could confound the results of the study * history of alcohol or drug dependence or abuse * current use of anticonvulsant or narcotic medications.
insulin resistance in relation to hyperthyroidism and hypothyroidism

Conditions: Insulin Resistance

Summary: insulin resistance and its relation to hyperthyrodism and hypothyroidism

thyroid hormones (th) play an important role in regulating energy balance, metabolism of glucose, and lipids. while th oppose the action of insulin and stimulate the hepatic gluconeogenesis and glycogenolysis they up-regulate the expression of genes such as glucose transporter type-4 (glut--4) and phosphoglycerate kinase, involved in glucose transport and glycolysis, respectively, thus acting synergistically with insulin facilitating glucose disposal and utilization in peripheral tissues. this indicates a possible interplay between thyroid status and insulin sensitivity. homeostatic model assessment (homa) is a method for assessing β-cell function and insulin resistance (ir) from basal (fasting) glucose and insulin or c-peptide concentrations. the homeostasis model assessment (homa) for ir (homa-ir) derives estimates of insulin sensitivity from the mathematical modeling of fasting plasma glucose and insulin concentrations. homeostatic model assessment for insulin resistance (homa - ir) based on fasting glucose and insulin measurements; derived from the product of the insulin and glucose values divided by a constant, that is, calculated by using the following formula: fasting glucose (mg/dl) x fasting insulin (mu/l) / 405 (for si units: fasting glucose (mmol/l) x fasting insulin (mu/l) / 22.5) , a value greater than 2 indicates insulin resistance . in both hyper- as well as hypothyroid groups, there was significant increase in ldl levels. the amount of insulin specifically bound and the number of insulin receptors per cell were inversely correlated with the ldl level. the number of insulin receptors and the amount of insulin bound in the tested subjects with increased ldl were correspondingly low.

Eligibility criteria:
inclusion criteria: * adult pations above 18 years old exclusion criteria: * any patients with diabetes mellitus
bone mineral density in children with graves' disease

Conditions: Bone Density, Low; Bone Mineral Density in Children With Graves' Disease

Summary: to evaluate bone mineral density in children with graves' disease


Eligibility criteria:
inclusion criteria: * age at enrollment ≥2 years to \< 18 years * both sexes * the patients should be diagnosed with graves' exclusion criteria: * patients less than 2 years * patients more than 18 years * controlled gd patients on antithyroid * patients with other endocrine diseases
cad-cam peek framework for all-on-4 implants

Conditions: Bone Loss

Summary: this study was conducted to evaluate the clinical peri-implant soft tissue changes during the first year after occlusal loading and the ridge base relation after 3 years for mandibular computer-aided design and computer-aided manufacturing (cad/cam) screw-retained implant-supported hybrid prosthesis of polyetheretherketone (peek) framework utilized with all-on-four treatment concept.

sixteen completely edentulous patients were rehabilitated by four implants following the all-on-four protocol. after 3 months, the definitive prosthesis was constructed to be a screw-retained cad-cam milled framework from the modified peek (biohpp), bonded to polymethylmethacrylate teeth and a pink-shaded indirect light-polymerized nano-filled composite resin imitating the soft tissues. peri-implant soft tissue changes regarding plaque, bleeding, gingival scores, and probing depth were evaluated at prosthesis insertion (t0), 6 months (t1), and 12 months (t2) after insertion. also, monitoring of the ridge base relation was performed using cone-beam computed tomography cbct at the time of insertion (t0), and 1 year (t1), 2 years (t2), and 3 years (t3) after mandibular fixed detachable all-on-four framework insertion.

Eligibility criteria:
inclusion criteria: * completely edentulous maxillary and mandibular ridges with sufficient mandibular bone height in the inter-foraminal area confirmed with panoramic x-rays. * all selected patients will be with sufficient inter-arch space and restorative space. * all selected patients will have apparently healthy ridge covered by compressible oral mucosa and free from any ridge flabbiness. exclusion criteria: * patients with systemic diseases that contraindicate implant placement such as hematologic diseases, serious problems of coagulation and diseases of the immune system. also, metabolic diseases related to bone resorption such as uncontrolled diabetics or osteoporosis will be also excluded * history of para-functional habits (bruxism, clenching), smoking and alcoholism. * history of radiation therapy in the head and neck region.

Keywords: all-on-four implant cad-cam peek framework
expression of cd44, pcna and e-cadherin in pterygium tissue

Conditions: Pterygium

Summary: purpose: pterygium is a common ocular surface disease defined by fibrovascular conjunctival growth extending onto the cornea. its pathogenesis remains unclear. in severe cases, it may extend into the central cornea, inducing irregular corneal astigmatism and causing loss of vision. cd44( phagocytic glycoprotein-1 ) is involved in the organization of certain cellular processes, for instance, cell adhesion, division, and migration, by binding with its main ligand, hyaluronic acid. proliferating cell nuclear antigen (pcna) is a proliferation marker in the nucleus. e-cadherin is a calcium-dependent transmembrane glycoprotein that plays a significant role in the protection of tissue integrity and cell-to-cell adhesion. this study aimed to determine the role of cd44, proliferating cell nuclear antigen (pcna), and e-cadherin in pterygium formation and recurrence.

methods:60 patients with pterygium will be enrolled in the study and conjunctival samples will be collected from 30 patients to form the control group. cd44, pcna and e-cadherin expressions in surgically removed pterygium will be compared with tissue samples from normal control group. ibm spss (statistical software) version 26.0 will be used for statistical analyses.

Eligibility criteria:
inclusion criteria: patient with pterygium - exclusion criteria: patient with pseudopterygium -

Keywords: pcna, cd44 e-cadherin immunohistochemistry pterygium
a phase ib, open-label, multicenter study of the safety and pk of the combination of rhumab2c4 (omnitarg), a recombinant humanized antibody to her2, and capecitabine (xeloda) in patients with advanced solid tumors

Conditions: Solid Tumor

Summary: this study will evaluate the safety, tolerability, and pharmacokinetics of the combination of rhumab 2c4(perjeta) and capecitabine (xeloda) in participants with advanced solid tumors that have progressed during or after standard therapy, or for which no standard therapy is available. participants will be enrolled and evaluated for dose-limiting toxicities (dlts) in escalating-dose cohorts in order to determine the maximum tolerated dose (mtd).


Eligibility criteria:
inclusion criteria: * adults at least 18 years of age * easter cooperative oncology group (ecog) performance status of 0 or 1 * life expectancy at least 12 weeks * locally advanced or metastatic solid tumor with at least 1 measurable lesion, which has progressed during/after standard therapy * human epidermal growth factor receptor 2 (her2)-negative among participants with breast cancer * negative pregnancy test or use of an adequate contraceptive method among women of childbearing potential * adequate hematologic, hepatic, and renal function exclusion criteria: * clinical evidence of central nervous system (cns) metastases * prior chemotherapy, radiotherapy, or immunotherapy within 4 weeks, or hormone therapy within 2 weeks of study day 1 * history of palmar plantar syndrome grade 2 or worse, or any unresolved residual chemotherapy effects * prior her2-active agents, continuous intravenous (iv) 5-fluorouracil, capecitabine, or other fluoropyrimidine * any investigational agent within 28 days of study start * prior cumulative doxorubicin dose greater than (\>) 360 mg/m\^2 or equivalent * significant cardiovascular disease * active/uncontrolled concurrent illness or infection- * major surgery or trauma within 4 weeks of study day 1
statins for prevention of contrast induced nephropathy

Conditions: Contrast Induced Nephropathy

Summary: in this randomized study the investigators wish to explore the role of pre-procedural statin therapy for the prevention of contrast induced nephropathy in patients with moderate-to-severe renal dysfunction, submitted to elective coronary or angioplasty.


Eligibility criteria:
inclusion criteria: * patients with pre-angiographic estimated creatinine clearance \< 60 ml/min exclusion criteria: * contrast medium administration within the previous 10 days * end-stage renal failure requiring dialysis * refusal to give informed consent * previous therapy with statin

Keywords: contrast induced nephropathy
atrophic age-related macular degeneration (amd) treated with intravitreal injections of umbilical cord blood platelet-rich plasma (cb-prp): a pilot study

Conditions: Dry Age-related Macular Degeneration

Summary: the objective of the study will be to evaluate the efficacy of intravitreal injections of umbilical cord blood platelet-rich plasma (cb-prp) in order to reduce or stabilize the atrophic progression in dry age-related macular degeneration (amd)


Eligibility criteria:
inclusion criteria: * age ≥65 years * bilateral dry-amd * etdrs-corrected visual acuity between (or equal to) 1/10 and 4/10 * no concomitant ocular pathology (e.g., glaucoma, amblyopia) or systemic pathology that would result in a bias for primary goal assessment * signature of informed consent exclusion criteria: * age \< 65 years * pregnancy * previous inflammatory/infectious events involving the eyes * eye trauma, diabetes, or disease potentially damaging to the visual system, even in the absence of impairment at the time of intake * previous intravitreal treatments. * refusal to sign informed consent.
glp-1 response and effect in individuals with obesity causing genetic mutations

Conditions: Obesity

Summary: the obesity epidemic is attributable to dietary and behavioral trends acting on a person's genetic makeup to determine body mass and susceptibility to obesity-related diseases. furthermore, common forms of obesity have a strong hereditary component and many genetic pathways that contribute to obesity have already ben identified. glucagon-like peptide-1 (glp-1) is an incretin hormone that potentiates glucose-stimulated insulin secretion. however, glp-1 also acts as an appetite-inhibiting hormone affecting the appetite center in the hypothalamus. today, glp-1 receptor agonists are available for the treatment of type 2 diabetes, and their treatment potential in obesity is an area of active research. the aim of this study is to explore if the appetite inhibiting effect of glp-1 is intact in people diagnosed with obesity causing genetic disorders and to investigate the physiological role of glp-1 on food intake and appetite regulation in this group.

* exploration of the physiological role of glp-1 concerning food intake and appetite regulation in obese adults diagnosed with obesity related genetic disorders. * assessment of the effect of glp-1 on body composition, bone mineral density, energy expenditure, cardiac function, glucose tolerance, insulin sensitivity, lipid concentrations and neuroendocrine function. * assessment of the impact of the leptin induced adaptive thermogenesis response in the weight reduced study participants. * investigating the alteration of the composition of gut bacteria as well as subjective ratings of satiety and hunger before after supplement with glp-1.

Eligibility criteria:
inclusion criteria: * bmi above 28 (kg/m2) * age 18-65 years * otherwise healthy exclusion criteria: * pregnancy or breastfeeding * type 2 diabetes * suffering from severe medical conditions recruitment for this study finished november 2015

Keywords: obesity obesity genetics glp-1 glp-1 receptor agonists
attitudes toward physical activity and nutrition intervention during cancer treatment

Conditions: Breast Neoplasms; Body Weight Changes

Summary: twenty-five women will be followed through their breast cancer treatment. the women will be asked to provide their opinions and desires for lifestyle intervention at different times throughout treatment. in addition, basic clinical data will be collected . the primary goal of this pilot study is to investigate the physical and behavioral changes that occur in patients receiving treatment for breast cancer.

in this cross sectional, longitudinal, observational study, 25 women will be followed through their treatment for stage i-iii breast cancer. the women will be asked to provide their opinions and desires for lifestyle intervention at four timepoints throughout treatment. in addition to qualitative data, basic clinical data will be collected (anthropometrics, vital signs, dietary intake, and physical activity). the primary goal of this pilot study is to investigate the anthropometric and behavioral changes that occur in patients undergoing adjuvant chemotherapy for breast cancer. aim 1: to better understand patients' attitudes toward and perceived barriers to nutrition and physical activity interventions during neoplastic treatment. hypothesis: patients' reported attitudes, motivation, and perceived barriers will change throughout treatment. aim 2: to measure the physical and metabolic changes that occur throughout neoplastic treatment for breast cancer. hypothesis: over 50% of the participants will gain body weight during treatment and metabolic parameters will trend with body weight change.

Eligibility criteria:
inclusion criteria: * female * ≥18 years of age * diagnosed with stage i, ii or iii breast cancer with plans to undergo endocrine and/or chemotherapy treatment (radiation in combination with one or more of these therapies is acceptable) * willing to complete up to 4 clinic visits exclusion criteria: * have received neoadjuvant therapy for current diagnosis * currently receiving adjuvant chemotherapy or other adjuvant therapy that was initiated prior to study enrollment * history of cancer and neoplastic treatment

Keywords: breast cancer